Dinatrium-7-[[carboxylato(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-en-2-carboxylat

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Achtung

• Gefahrenhinweise

  H317：Kann allergische Hautreaktionen verursachen.

  H334：Kann bei Einatmen Allergie, asthmaartige Symptome oder Atembeschwerden verursachen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P342+P311：Bei Symptomen der Atemwege: GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

Latamoxef sodium Chemische Eigenschaften,Einsatz,Produktion Methoden

• R-Sätze Betriebsanweisung:

  R42/43:Sensibilisierung durch Einatmen und Hautkontakt möglich.

• S-Sätze Betriebsanweisung:

  S22:Staub nicht einatmen.
  S36/37:Bei der Arbeit geeignete Schutzhandschuhe und Schutzkleidung tragen.
  S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).

• Beschreibung

  Latamoxef was synthesized by Shionogi Pharmaceuticals in 1975 starting with benzylpenicillin and using a novel drug design. The oxacephem nucleus, in which the sulfur atom had been replaced by oxygen, was substituted with a methoxyl group at the 7α position, as in the cephamycins. A carboxyl moiety and a hydroxybenzyl group were added at the 7β position, as in carbenicillin, and a methyltetrazolylthiomethyl group was attached at the 3 position. These substitutions resulted in a strong activity against gram-negative bacteria and a high resistance to the action of βlactamase, along with excellent activity against Pseudomonas aeruginosa, even though the compound has no activity against Staphylococcus aureus.

• Originator

  Moxam,Lilly,US,1981

• Verwenden

  Moxalactam Sodium is an oxacephem antibiotic. Moxalactam Sodium is more effective against Escherichia coli and Pseudomonas aeruginosa than cephalosporins.

• Verwenden

  Antibacterial;Bacterial transpeptidase inhibitor

• Manufacturing Process

  To a stirred suspension of p-(p-methoxybenzyloxy)-phenylmalonic acid (125 mg) in methylene chloride (3 ml) are added triethylamine (55 l) and oxalyl chloride (26 l) at -15°C, and the suspension is stirred for 40 minutes at 0°C. The mixture is added to a solution of diphenylmethyl 7β-amino-7α-methoxy-3- (1-methyltetrazol-5-yl)thiomethyl-1-oxadethia-3-cephem-4-carboxylate (100 mg) in methylene chloride (3 ml) and pyridine (63 l), and the mixture is stirred for 30 minutes at 0°C. The reaction mixture is diluted with ethyl acetate, washed with aqueous 2N-hydrochloric acid and water, dried over sodium sulfate, and concentrated to give crude product (212 mg), which is chromatographed on silica gel (20 g) and eluted with a mixture of ethyl acetate and acetic acid (99:1) to give diphenylmethyl-7β-[α-p-(pmethoxybenzyloxy)phenyl-α-carboxyacetamido]-7α-methoxy-3-(1- methyltetrazol-5yl)thiomethyl-1-oxadethia-3-cephem-4-carboxylate as foam (71 mg). Yield: 45%.
  To a solution of diphenylmethyl-7β-[α-p-(p-methoxybenzyl)-oxy-phenyl-α-pmethoxybenzyl-oxycarbonil-acetamido]-7α-methoxy-3-(1-methyltetrazol-5- yl)thiomethyl-1-oxadethia-3-cephem-4-carboxylate (1.20 g) in methylene chloride (24 ml) are added anisole (2.4 ml) and a solution of aluminum chloride (2.58 g) in nitromethane (12 ml) at 0°C under nitrogen. After stirring for 15 minutes at 0°C, the mixture is poured into cold 5% sodium hydrogen carbonate aqueous solution (100 ml) and filtered to remove the formed precipitate. The filtate is washed twice with methylene chloride (2 x 100 ml), acidified with 2N-hydrochloric acid to pH 2.60, and poured in a column of high porous polymer HP-20 (60 ml) sold by Mitsubishi Chemical Industries Ltd. The column is washed with water (300 ml) and eluted with methanol. The eluate is concentrated under reduced pressure at room temperature. The residue is dissolved in methanol, treated with active carbon, and concentrated under reduced pressure to give 7β(α-p-hydroxyphenyl-α-carboxyacetamido)-7β- methoxy-3-(1-methyl-tetrazol-5-yl)thiomethyl1-oxadethia-3-cephem-4- carboxylic acid as powder (595 mg) decomposing at 125°C to 132°C. Yield: 88.5%.
  To a solution of 7β(α-p-hydroxyphenyl-α-carboxyacetamido)-7α-methoxy-3-(1- methyl-tetrazol-5-yl)thiomethyl1-oxadethia-3-cephem-4-carboxylic acid (359 mg) in methanol (7 ml) is added a solution of sodium 2-ethylhexanoate in methanol (2 mols/liter; 1.73 ml) at room temperature. After stirring for 10 minutes, the reaction mixture is diluted with ethyl acetate, stirred for 5 minutes, and filtered to collect separated solid, which is washed with ethyl acetate, and dried to give disodium salt of 7β(α-p-hydroxyphenyl-α- carboxyacetamido)-7α-methoxy-3-(1-methyl-tetrazol-5-yl)thiomethyl1- oxadethia-3-cephem-4-carboxylic acid (342 mg). Yield: 888%. Colorless powder. MP decomposition from 170°C.

• Trademarks

  Moxam (Lilly).

• Therapeutic Function

  Antiinfective

• Biologische Aktivität

  moxalactam (sodium salt) is a β-lactam antibiotic.β-lactam antibiotics (beta-lactam antibiotics) are a class of broad-spectrum antibiotics that contain a beta-lactam ring in their molecular structures. most β-lactam antibiotics act by inhibiting cell wall biosynthesis.moxalactam is an oxacephem antibiotic and inhibits most commonly occurring gram positive, gram negative, and anaerobic bacteria. moxalactam was more active against klebsiella and e coli than cefoperazone. moxalactam did not inhibit methicillin-resistant s. aureus and enterococci. moxalactam had been extremely active against haemophilis and neisseria gonorrhoeae. moxalactam was extremely resistant to hydrolysis by all plasmid and chromosmal β-lactamases [1]. in certain situations, moxalactam impaired normal hemostasis and prolonged bleeding time [2].

• Einzelnachweise

  [1]. neu hc. the in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics. annu rev pharmacol toxicol. 1982;22:599-642.
  [2]. sattler fr, weitekamp mr, ballard jo. potential for bleeding with the new beta-lactam antibiotics. ann intern med. 1986 dec;105(6):924-31.

Latamoxef sodium Upstream-Materialien And Downstream Produkte

Dinatrium-7-[[carboxylato(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-en-2-carboxylat Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(209)Suppliers

64953-12-4, Latamoxef sodium Verwandte Suche: